Combined use of prostate-specific antigen density and PI-RADS score to optimize prostate biopsy strategy
Introduction: We aimed to compare detection rates of prostate cancer (PCa) and clinically significant prostate cancer (csPCa) between MRI-targeted and transrectal ultrasound (TRUS)-guided systematic transrectal biopsy, and to evaluate prostate-specific antigen (PSA) density (PSAD) as a tool to refine biopsy strategies and reduce unnecessary systematic biopsies. Materials and methods: We retrospectively reviewed 630 biopsy-naïve men who underwent combined MRI-targeted and systematic prostate biopsy in 2023. The mean age was 67.5 years, mean PSA was 6.69 ng/mL, and mean prostate volume was 48.4 cm 3 . Patients were stratified into four PSAD categories: <0.10, 0.10–<0.15, 0.15–<0.20, and ≥0.20 ng/mL/cm 3 . Cancer detection rates were assessed according to biopsy modality, Prostate Imaging-Reporting and Data System (PI-RADS) score, and PSAD. Multivariable logistic regression analysis was performed to identify predictors of csPCa. Results: Overall, PCa was detected in 78.1% (492/630) of patients, of whom 87.0% (428/492) had csPCa. Increasing PSAD was associated with csPCa and a greater number of positive biopsy cores ( p < 0.001). In the multivariable analysis, PSAD remained an independent predictor of csPCa (odds ratio [OR] 3.87, p < 0.001). PI-RADS score was also independently associated with higher-grade disease. PSAD was significantly correlated with PI-RADS score. Among men with PI-RADS 3 lesions, patients with PSAD ≥ 0.20 ng/mL/cm 3 demonstrated 8.5-fold higher odds of csPCa compared with those with PSAD < 0.10 ng/mL/cm 3 . Systematic biopsy consistently detected additional csPCa that would have been missed by targeted biopsy alone across all PSAD strata. Conclusions: PSAD is an independent predictor of PCa and csPCa and complements PI-RADS scoring for biopsy risk stratification, especially for PI-RADS 3 lesions. Systematic biopsy continues to provide additional diagnostic yield beyond MRI-targeted biopsy alone. These findings support the continued use of supplemental sampling in conjunction with MRI-targeted biopsy while highlighting the need for prospective studies to determine whether less extensive approaches, such as targeted plus perilesional sampling, can provide comparable diagnostic performance.
Authors
- Dharam M. Ramnani
- Yousif M. Shakroo
- Junqi Qian (ORCID: https://orcid.org/0009-0009-7967-238X)
- Fadi M. Shakroo
Publication Details
- Journal
- Academia Medicine and Health
- Published
- 2026-11-13
- DOI
- https://doi.org/10.20935/acadmedhealth8636
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00